T-Cell Receptor Discovery for Engineered T-cell Therapy for Human Cancers

用于人类癌症工程 T 细胞疗法的 T 细胞受体发现

• 批准号: 10317346
• 负责人: STEVEN K. LIBUTTI
• 金额: $ 150.85万
• 依托单位: RBHS -CANCER INSTITUTE OF NEW JERSEY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-03-01 至 2024-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10317346
• 关键词: Address; Advanced Malignant Neoplasm; Basic Science; Biometry; Cancer Burden; Cancer Center; Cancer Control; Cancer Institute of New Jersey; Cancer Patient; Cancer Survivor; Catchment Area; Cell Separation; Cessation of life; Clinical Research; Clinical Trials; Collaborations; Comprehensive Cancer Center; Education; Family member; Flow Cytometry; Genomic Instability; Genomics; Growth; Health Sciences; Health system; Histopathology; Human; Immunologic Monitoring; Incidence; Individual; Infrastructure; Institutes; Institution; Malignant Neoplasms; Mission; Names; National Cancer Institute; New Jersey; Oncology; Pathogenesis; Patients; Peer Review; Pharmacy facility; Population; Population Heterogeneity; Population Research; Population Sciences; Positioning Attribute; Precision therapeutics; Prevention; Process; Public Health; Publications; Publishing; Quality of life; Research; Research Activity; Research Personnel; Resource Sharing; Resources; Risk; SEER Program; Science; Services; Statutes and Laws; Strategic Planning; Structure; T cell therapy; T-Cell Receptor; Talents; Therapeutic Intervention; Training and Education; Translating; Translational Research; Translations; Universities; Vision; anticancer research; authority; biobank; biomedical informatics; cancer care; cancer genetics; cancer pharmacology; cancer prevention; cancer risk; care delivery; clinical care; clinical investigation; engineered T cells; genome editing; innovation; inter-institutional; interdisciplinary collaboration; member; metabolomics; mortality; multidisciplinary; neoplasm registry; next generation; oncology service; programs; public health relevance; screening; small molecule; tumor metabolism

RESEARCH PLAN – RUTGERS CANCER INSTITUTE OF NEW JERSEY OVERALL PROJECT SUMMARY/ABSTRACT The Rutgers Cancer Institute of New Jersey (CINJ) is a matrix/consortium (with Princeton University) and New Jersey’s only NCI-designated Comprehensive Cancer Center, serving a diverse population of 8.9 million people. CINJ focused the strengths and resources of the major research institutions in NJ on addressing the cancer burden in its catchment area (NJ). The rapid trajectory of CINJ’s growth validated the initial vision that one of the Nation’s largest public universities of the health sciences would rapidly bring forth an NCI-designated Cancer Center. CINJ has 227 members (206 Rutgers, 19 Princeton, and 2 collaborating). The State Cancer Registry and Surveillance, Epidemiology, and End Results (SEER) Program was moved to CINJ in 2011, and as a result of state legislation in 2013, CINJ became an independent institute of Rutgers University, optimizing CINJ’s potential for growth, transdisciplinary collaboration, and impact across the catchment area. In FY2018, CINJ received over $68 million in support from Rutgers and Princeton, the State, the Health System, and philanthropy. Direct peer-reviewed support increased ~16%. Members published 3,664 cancer focused publications since 2011 (20% inter- and 24% intra-programmatic, 55% inter-institutional). In January 2017, Steven K. Libutti was appointed Director of CINJ and Vice Chancellor for Cancer Programs for Rutgers Biomedical and Health Sciences (RBHS). In a strategic partnership with the RWJBarnabas Health System, Libutti was named Senior Vice President for Oncology Services. CINJ is now positioned to coordinate both cancer research and care throughout its catchment area. An iterative strategic planning process resulted in reorganization of research Programs to increase collaborations, cancer focus, translation, and investigator-initiated clinical trials. These five Programs are: 1) Cancer Metabolism and Growth (CMG), 2) Genomic Instability and Cancer Genetics (GICG), 3) Cancer Pharmacology (CP), 4) Clinical Investigations and Precision Therapeutics (CIPT), and 5) Cancer Prevention and Control (CPC). These Programs are supported by eight shared resources (Biomedical Informatics, Biometrics, Biorepository and Histopathology Services, Comprehensive Genomics, Flow Cytometry/Cell Sorting, Genome Editing, Metabolomics, and Research Pharmacy), with two developing shared resources (Immune Monitoring, Small Molecule Screening). The Statewide authority of CINJ derives from its status as the only NCI-designated Cancer Center; extensive and direct support by the State of New Jersey to serve as the State’s oncology resource; opportunities to conduct translational and population research within the most diverse and densely populated State in the nation; and the synergistic opportunities for collaboration across outstanding research institutions. This supports CINJ’s mission to reduce the burden of cancer in its catchment by advancing cancer research, prevention, screening and education.

Rutgers Cancer Institute OF新泽西Overall 项目总结/摘要 新泽西罗格斯癌症研究所（CINJ）是一个矩阵/联盟（与普林斯顿大学合作）和新泽西州 泽西岛唯一一家由NCI指定的综合癌症中心，为890万人提供服务。 CINJ集中了新泽西州主要研究机构的优势和资源来解决癌症问题。 在其集水区（NJ）的负担。CINJ的快速发展验证了最初的愿景， 全国最大的健康科学公立大学将迅速推出一个NCI指定的癌症 中心CINJ有227名成员（罗格斯大学206名，普林斯顿大学19名，合作2名）。州癌症登记系统 监测、流行病学和最终结果（SEER）计划于2011年转移到CINJ， 2013年，CINJ成为罗格斯大学的一个独立研究所，优化了CINJ的 增长潜力、跨学科合作和对整个流域的影响。2018财年，CINJ 从罗格斯大学和普林斯顿大学，国家，卫生系统和慈善事业获得了超过6800万美元的支持。 直接的同行评审支持增加了~ 16%。自2013年以来，会员发表了3，664篇癌症重点出版物 2011年（方案间20%，方案内24%，机构间55%）。2017年1月，Steven K. Libutti是 被任命为CINJ主任和罗格斯大学生物医学和健康癌症项目副校长 科学（RBHS）。在与RWJBarnabas卫生系统的战略合作伙伴关系中，Libutti被任命为高级 肿瘤服务副总裁。CINJ现在定位于协调癌症研究和护理 在整个流域。一个反复的战略规划过程导致了研究的重组 增加合作，癌症焦点，翻译和制药商发起的临床试验的计划。这五 方案是：1）癌症代谢和生长（CMG），2）基因组不稳定性和癌症遗传学（GICG）， 3)癌症药理学（CP），4）临床研究和精确治疗（CIPT），5）癌症 预防和控制（CPC）。这些计划由八个共享资源（生物医学）支持。 信息学、生物识别、生物储存和组织学服务、综合基因组学、流程 细胞计数/细胞分选，基因组编辑，代谢组学和研究药学），两个开发共享 资源（免疫监测，小分子筛选）。CINJ的全州权威来自于其 作为唯一的NCI指定癌症中心的地位;由新泽西州广泛和直接的支持， 作为国家的肿瘤学资源;机会进行转化和人口研究内 最多样化和人口稠密的国家在全国;和协同合作的机会， 优秀的研究机构。这支持CINJ的使命，以减少其集水区的癌症负担 通过推进癌症研究、预防、筛查和教育。